Abstract Library

#1213 Everolimus (EVE)-Induced Hyperglycemia (HG) in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs): Clinical Relevance and Predictive Value

Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Custodio A

Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,

Keywords: NET, everolimus, hyperglycemia ,

#1153 Prognostic Role of Diabetes Mellitus (DM) and Metformin (MET) Therapy in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumors (NETs) Treated with Everolimus (EVE)

Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Custodio A

Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,

Keywords: NET, diabetes, metformin, everolimus,